# Proxybio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proxybio

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Latest round: Seed (Jul 5, 2021)
- Investors on record: 1

## About

Established in 2020 and based in Shenzhen, China, Proxybio is a biological technology company that focuses on drugs in the field of mRNA. The founder Dr. Jiaqi Lin has more than ten years of experience in nanobiological research. At present, the core team all come from laboratory of Massachusetts Institute of Technology. In July 2021, Proxybio raised series seed funding from new investor Bio Venture.

The company has a self-develop mRNA high-throughput synthesis platform which provides mRNA drug product for customer.

## Funding rounds

- Seed, Jul 5, 2021 — YuanBio Venture

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Seed